Clinical Problems of IgM Monoclonal Gammapathies
Authors:
T. Pika 1; P. Flodr 2; M. Novák 3; P. Lochman 4; P. Látalová 2; J. Minařík 1; V. Ščudla 1
Authors place of work:
III. interní klinika – NRE, LF UP a FN Olomouc
1; Ústav klinické a molekulární patologie, LF UP a FN Olomouc
2; Hematoonkologická klinika, FN Olomouc
3; Oddělení klinické biochemie, FN Olomouc
4
Published in the journal:
Klin. Biochem. Metab., 22 (43), 2014, No. 2, p. 61-64
Summary
Monoclonal gammopathies associated with presence of IgM paraprotein form a heterogeneous group of diseases. Monoclonal gammopathy of undetermined significance (MGUS) of IgM type presents a potentially malignant condition with a risk of neoplastic transformation into a different type of lymphoproliferative disorder than the forms of MGUS with other paraprotein isotypes. Most often it transforms into Waldenström´s macroglobulinemia, which is a lymphoproliferative disorder (lymphoplasmocyte lymphoma) with the production of IgM paraprotein. The disease is relatively indolent, requiring systemic treatment only in the case of significant tumor clone burden together with the presence of symptoms associated with high levels or certain qualitative characteristics of IgM protein. IgM multiple myeloma and IgM AL amyloidosis are rare disorders in the differential diagnostics of IgM paraproteinemia. Differentiation of individual conditions can be difficult, and requires the cooperation of several specialists.
Key words:
IgM, monoclonal gammopathy of undetermined significance, multiple myeloma, amyloidosis, Waldenström´s macroglobulinemia.
Zdroje
1. Grönwall, C., Vas, J., Silverman, G. J. Protective roles of natural IgM antibodies. Front. Immunol. 2012, 3, p. 1 – 10.
2. Qamar, N., Fuleihan, R. L. The hyper IgM syndromes. Clinic. Rev. Allerg. Immunol. DOI 10.1007/s12016-013-8378-7.
3. Stone, M. J. Waldenström´s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin. Lymph. Myeloma 2009, 9, p. 97-99.
4. Salkie, M. L. A retrospective study of the relative utility of electrophoresis, immunoelectrophoresis, immunofixation, and nephelometry in the investigation of serum proteins. Clin. Biochem. 1996, 29, p. 39-42.
5. Bailey, D., Lem-Ragosnig, B., Chan, P. C. Challenges in identifying some IgM monoclonal proteins by capillary serum protein electrophoresis. Clin. Biochem. 2013, 46, p. 1776-1777.
6. Ščudla, V., Pika, T., Heřmanová, Z. Hevylite – nová analytická metoda v diagnostice a hodnocení průběhu monoklonálních gamapatií. Klin. Biochem. Metab. 2010, 18, p. 62-68.
7. Luigetti, M., Padua, L., Mazza, S. et al. Clinical-neurophysiological correlations in a series of patients with IgM-related neuropathy. Clin. Neurophysiol. 2013, 124, p. 1899-1903.
8. Kyle, R. A., Therneau, T. M., Rajkumar, S. V. et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003, 102, p. 3759-3764.
9. Kyle, R. A., Dispenzieri, A., Kumar, S., Larson, D., Therneau, T., Rajkumar, S. V. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström´s macroglobulinemia (SWM). Clin. Lymph. Myeloma 2011, 11, p. 74-76.
10. Greco, A., Tedeschi, A., Verettoni, M. et al. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy. Clin. Lymph. Myeloma 2011, 11, p. 77-79.
11. Gertz, M. A., Kyle, R. A. Amyloidosis with IgM monoclonal gammopathies. Semin. Oncol. 2003, 30, p. 325-328.
12. Gertz, M. A., Buadi, F. K., Hayman, S. R. IgM amyloidosis: clinical features in therapeutic outcomes. Clin. Lymph. Myeloma 2011, 11, p. 146-148.
13. King, R. L., Howard, M. T., Hodnefield, J. M., Morice, W. G. IgM multiple myeloma. Pathologic evaluation of a rare entity. Am. J. Clin. Pathol. 2013, 140, p. 519-524.
14. Schuster, S. R., Rajkumar, S. V., Dispenzieri, A. et al. IgM multiple myeloma: disease definition, prognosis, and differentation from Waldenström´s macroglobulinemia. Am. J. Hematol. 2010, 85, p. 853-855.
15. Avet-Loiseau, H., Garand, R., Lodé, L. et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma. Blood 2003, 101, p. 1570-1571.
16. Owen, R. G., O´Connor, S. J. M., Bond, L. R., de Tute, R. M., Rawstron, A. C. Translocation t(14;16) in IgM multiple myeloma. Brit. J. Hematol. 2011, 155, p. 395-408.
17. Owen, R. G., Feyler, S., O´Connor, S. J. M., Bond, L. R., de Tute, R. M., Rawstron, A. C. Defining IgM multiple myeloma. Am. J. Hematol. 2011, 86, p. 717.
18. Reece, D. E., Vesole, D. H., Shrestha, S. et al. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin. Lymph. Myeloma 2010, 10, p. 458-463.
19. Owen, R. G., Treon, S. P., Al-Katib, A. et al. Clinicopathological definition of Waldenström´s macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenström´s macroglobulinemia. Semin. Oncol. 2003, 30, p. 110-115.
20. Paiva, B., Montes, M. C., Garcia-Sanz, R. et al. Multiparameter flow cytometry for the identification of the Waldenström´s clone in IgM-MGUS and Waldenström´s macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 2014, 28, p. 166-173.
21. Treon, S. P., Xu, L., Yang, G. et al. MYD88 L265P somatic mutation in Waldenström´s macroglobulinemia. N. Engl. J. Med. 2012, 367, p. 826-833.
22. Landgren, O., Staud, L. MYD88 L265P somatic mutation in IgM MGUS. N. Engl. J. Med. 2012, 367, p. 2255-2256.
23. Kyle, R. A., Treon, S. P., Alexanian, R. et al. Prognostic markers and criteria to initiate therapy in Waldenström´s macroglobulinemia: consensus panel recommendations from the second international worshop on Waldenström´s macroglobulinemia. Semin. Oncol. 2003, 30, p. 116-120.
24. Dimopoulos, M. A., Anagnostopoulos, A. Treatment of Waldenström´s macroglobulinemia. Curr. Treat. Opt. Oncol. 2007, 8, p. 144-153.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2014 Číslo 2
Najčítanejšie v tomto čísle
- Clinical Problems of IgM Monoclonal Gammapathies
- Risk factors of Asymptomatic (Smoldering) Multiple Myeloma
- Diagnosis and stratification of systemic AL amyloidosis in the light of the 2013 Czech Myeloma Group recommendation
- The Standard of Analytical Quality of Glucometers